In the last years, the introduction of advanced imaging techniques, such as multiparametric magnetic resonance of the prostate (mpMRI) and prostate-specific membrane antigen positron emission tomography (PSMA-PET) scans, in addition to the availability of novel molecular markers, have shifted the paradigm of PCa screening, diagnosis, and treatment to a more individualized approach. This evidence concerns the gene FOLH1 and posterior cortical atrophy.